By report, he has been weak, confused since his last XRT treatment on friday, [**11-18**].
Pt has known hip, brain mets for which he is receiving XRT; he just completed a 10-treatment course for his hip mets and has received 2 treatments for his head, most recently on [**11-18**].
He was given ASA, Decadron 10 mg IV x 1, admitted for mgt.
LBP, s/p L4-5 laminectomy [**2108**] 5.  s/p Carpal tunnel release 6.
However, waveforms in the common carotid arteries may be indicative of a more proximal disease.
There is ventricular enlargement, but not substantially changed since previous exam.
Pt was initially started on heparin IV, but a decision was made to discontinue this given the pt's high fall risk and he was instead placed on aggrenox.
He was continued on decadron and a decision was made to stop XRT.
He was continued on decadron 4mg PO q6hrs.
A decision in conjunction with primary oncologist and family not to pursue further agressive treatment was made.
Medications on Admission: Meds on Admission: Atenolol 50 mg daily Zantac Vicodin PRN Decadron (?4mg [**Hospital1 **] as per son, unclear on dose)   Discharge Medications: 1.
Hydrocodone-Acetaminophen 5-500 mg Tablet Sig: 1-2 Tablets PO Q4-6H (every 4 to 6 hours) as needed for pain: hold for oversedation.
Docusate Sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 times a day).
Senna 8.6 mg Tablet Sig: One (1) Tablet PO BID (2 times a day) as needed for constipation.
Bisacodyl 5 mg Tablet, Delayed Release (E.C.)
Dexamethasone 4 mg Tablet Sig: One (1) Tablet PO Q12H (every 12 hours).
Captopril 25 mg Tablet Sig: One (1) Tablet PO TID (3 times a day).
Nicotine 21 mg/24 hr Patch 24HR Sig: One (1) Patch 24HR Transdermal DAILY (Daily).
Pantoprazole 40 mg Tablet, Delayed Release (E.C.)
Atorvastatin 10 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Dipyridamole-Aspirin 200-25 mg Cap, Multiphasic Release 12 HR Sig: One (1) Cap PO BID (2 times a day).
Heparin (Porcine) 5,000 unit/mL Solution Sig: One (1) mL Injection TID (3 times a day).
Take your medications as prescribed.
